We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

516 hedge funds and large institutions have $18.4B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2021 Q1 according to their latest regulatory filings, with 95 funds opening new positions, 188 increasing their positions, 187 reducing their positions, and 71 closing their positions.

New
Increased
Maintained
Reduced
Closed

35% more funds holding in top 10

Funds holding in top 10: 2331 (+8)

34% more first-time investments, than exits

New positions opened: 95 | Existing positions closed: 71

23% more capital invested

Capital invested by funds: $14.9B → $18.4B (+$3.49B)

22% more call options, than puts

Call options by funds: $200M | Put options by funds: $163M

4% more funds holding

Funds holding: 497516 (+19)

1% more repeat investments, than reductions

Existing positions increased: 188 | Existing positions reduced: 187

Holders
516
Holders Change
+19
Holders Change %
+3.82%
% of All Funds
9.06%
Holding in Top 10
31
Holding in Top 10 Change
+8
Holding in Top 10 Change %
+34.78%
% of All Funds
0.54%
New
95
Increased
188
Reduced
187
Closed
71
Calls
$200M
Puts
$163M
Net Calls
+$36.6M
Net Calls Change
-$132M

HZNP Hedge Fund Activity: Q1 2021 in Review

516 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q1 2021, worth a combined $18.4B — up 23% from $14.9B a quarter earlier.

Buyers outnumbered sellers: 95 funds opened new HZNP positions and 71 closed out — a net gain of 24 holders — while 188 added to existing stakes and 187 trimmed.

The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $110M. The largest seller was Renaissance Technologies, cutting an estimated $134M.

  • 516 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q1 2021, up from 497 in Q4 2020.
  • Funds reported $18.4B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q1 2021, up 23% quarter-over-quarter.
  • 95 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q1 2021 and 71 closed out, a net change of +24 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q1 2021 was Waddell & Reed Financial, an estimated $110M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q1 2021 was Renaissance Technologies, an estimated $134M sold.

Based on aggregated 13F filings for Q1 2021.